{"id":690,"date":"2024-03-14T12:51:39","date_gmt":"2024-03-14T11:51:39","guid":{"rendered":"https:\/\/aslabsci.com\/?page_id=690"},"modified":"2024-04-28T18:58:49","modified_gmt":"2024-04-28T16:58:49","slug":"active-substances-api","status":"publish","type":"page","link":"https:\/\/aslabsci.com\/en\/active-substances-api\/","title":{"rendered":"Active substances (API)"},"content":{"rendered":"<p>Active substances acting on the central nervous system:<\/p>\n<ul>\n<li>Amino acid neurotransmitters<\/li>\n<li>Acetylcholine<\/li>\n<li>Monoamine structure neurotransmitters<\/li>\n<li>Neurotransmitters with different structures, neuromodulators, and neuropeptides<\/li>\n<\/ul>\n<p>Active substances with psychotropic effects:<\/p>\n<ul>\n<li>First and second-generation antipsychotics<\/li>\n<li>Antidepressants:<\/li>\n<\/ul>\n<p>&#8211;\u00a0 Non-selective serotonin and norepinephrine reuptake inhibitors<br \/>\n&#8211; Selective serotonin reuptake inhibitors (SSRI)<br \/>\n&#8211; Selective norepinephrine reuptake inhibitors (SNRI)<br \/>\n&#8211; Selective serotonin and norepinephrine reuptake inhibitors (SSNRI)<br \/>\n&#8211; Norepinephrine and dopamine reuptake inhibitors (NDRI)<br \/>\n&#8211; Serotonin reuptake inhibitors with additional receptor activity<br \/>\n&#8211; Monoamine oxidase inhibitors<\/p>\n<ul>\n<li>Anxiolytics<\/li>\n<\/ul>\n<p>Active substances stimulating the central nervous system:<\/p>\n<ul>\n<li>Psychostimulants<\/li>\n<li>Analeptics<\/li>\n<li>Nootropics<\/li>\n<\/ul>\n<p>Active substances with psychodysleptic effects:<\/p>\n<ul>\n<li>NMDA receptor antagonists<\/li>\n<li>GABA-A receptor agonists<\/li>\n<li>\u03ba-opioid receptor agonists<\/li>\n<li>Cannabinoids<\/li>\n<\/ul>\n<p>Active substances used in the therapy of neurodegenerative diseases:<\/p>\n<ul>\n<li>Parkinson&#8217;s disease<\/li>\n<li>Huntington&#8217;s disease<\/li>\n<li>Alzheimer&#8217;s disease<\/li>\n<li>Amyotrophic lateral sclerosis<\/li>\n<li>Multiple sclerosis<\/li>\n<\/ul>\n<p>Active substances with sedative-hypnotic effects:<\/p>\n<ul>\n<li>Barbiturates<\/li>\n<li>Agonists of the benzodiazepine site of the GABA-A receptor<\/li>\n<li>Non-benzodiazepine agonists<\/li>\n<li>Agonists of melatonin receptors MT1 and MT2<\/li>\n<li>Orexin receptor antagonists OX1R and OX2R<\/li>\n<\/ul>\n<p>Active substances with antiepileptic effects of the first, second, and third generation<\/p>\n<p>Active substances with analgesic, antipyretic, and anti-inflammatory effects:<\/p>\n<ul>\n<li>Opioids<\/li>\n<li>Non-opioid substances with analgesic effects<\/li>\n<li>Nonsteroidal anti-inflammatory drugs (NSAIDs)<\/li>\n<li>Analgesic and antipyretic substances without clear acidic character, devoid of anti-inflammatory action<\/li>\n<\/ul>\n<p>Active substances used in the therapy of gout<\/p>\n<p>Active substances affecting the autonomic nervous system:<\/p>\n<ul>\n<li>Skeletal muscle relaxants<\/li>\n<li>Antihistaminic substances<\/li>\n<\/ul>\n<p>Active substances acting on the circulatory system and affecting blood clotting:<\/p>\n<ul>\n<li>Cardiac glycosides<\/li>\n<li>Phosphodiesterase inhibitors (PDE)<\/li>\n<\/ul>\n<p>Active substances with antiarrhythmic effects<\/p>\n<p>Substances used in ischemic heart disease<\/p>\n<p>Substances lowering blood pressure<\/p>\n<p>Substances used in disorders of peripheral and cerebral circulation<\/p>\n<p>Substances reducing blood lipid levels (hypolipemic drugs)<\/p>\n<p>Polyunsaturated fatty acids (PUFAs) and sitosterols (plant sterols)<br \/>\nDiuretic substances<\/p>\n<p>Substances used in diseases of the respiratory system<\/p>\n<p>Substances used in diseases of the gastrointestinal system<\/p>\n<p>Hormones and substances affecting the functions of the endocrine system<\/p>\n<p>Vitamins, both water-soluble and fat-soluble, in various physical and chemical forms<\/p>\n<p>Substances acting on pathogenic microorganisms &#8211; antibiotics and others<\/p>\n<p>Substances used in antitumor chemotherapy:<\/p>\n<ul>\n<li>Alkylating agents<\/li>\n<li>Platinum complex compounds<\/li>\n<li>Antimetabolites<\/li>\n<li>Antibiotics with antitumor activity<\/li>\n<li>Topoisomerase inhibitors<\/li>\n<li>Anthracycline antibiotics with antitumor activity<\/li>\n<li>Antimitotic substances<\/li>\n<li>Cytostatics with various structures and diverse mechanisms of action<\/li>\n<li>Hormones and antihormones<\/li>\n<li>Antitumor substances affecting the activity of cellular kinases<\/li>\n<li>Cell growth modulators affecting receptor tyrosine kinases<\/li>\n<li>Epidermal growth factor receptor (EGFR) inhibitors<\/li>\n<li>Small molecule EGFR inhibitors<\/li>\n<li>Angiogenesis inhibitors<\/li>\n<li>Tumor blood vessel growth regulators<\/li>\n<li>Inhibitors of vascular endothelial growth factor receptor (VEGFR)<\/li>\n<li>Small molecule VEGFR inhibitors<\/li>\n<li>Isoindole-1,3-dione derivatives with antiangiogenic activity<\/li>\n<li>Small molecule fibroblast growth factor receptor (FGFR) inhibitors<\/li>\n<li>Anaplastic lymphoma kinase (ALK) receptor kinase inhibitors<\/li>\n<li>Tropomyosin receptor kinase inhibitors<\/li>\n<li>FLT3 tyrosine kinase receptor inhibitors<\/li>\n<li>Cytoplasmic tyrosine kinase inhibitors<\/li>\n<li>Bcr-Abl kinase inhibitors<\/li>\n<li>Bruton&#8217;s tyrosine kinase (BTK) inhibitors<\/li>\n<li>Cytoplasmic serine-threonine kinase inhibitors<\/li>\n<li>RAF pathway inhibitors<\/li>\n<li>Mitogen-activated protein kinase (MEK) inhibitors<\/li>\n<li>mTOR kinase inhibitors<\/li>\n<li>Cyclin-dependent kinase (CDK 4\/CDK 6) inhibitors<\/li>\n<li>Phosphatidylinositol 3-kinase (PI3K) inhibitors<\/li>\n<li>Proteasome inhibitors<\/li>\n<li>Poly(ADP-ribose) polymerase (PARP) inhibitors<\/li>\n<li>Substances with epigenetic activity<\/li>\n<li>DNA methyltransferase inhibitors<\/li>\n<li>Histone deacetylase inhibitors<\/li>\n<li>Substances used in immuno-oncological chemotherapy<\/li>\n<li>Immunostimulating substances<\/li>\n<li>Immunosuppressive cytostatics<\/li>\n<li>Antimetabolites<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Active substances acting on the central nervous system: Amino acid neurotransmitters Acetylcholine Monoamine structure neurotransmitters Neurotransmitters with different structures, neuromodulators, and neuropeptides Active substances with psychotropic effects: First and second-generation antipsychotics Antidepressants: &#8211;\u00a0 Non-selective serotonin and norepinephrine reuptake inhibitors &#8211; Selective serotonin reuptake inhibitors (SSRI) &#8211; Selective norepinephrine reuptake inhibitors (SNRI) &#8211; Selective serotonin and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-690","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/pages\/690","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/comments?post=690"}],"version-history":[{"count":1,"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/pages\/690\/revisions"}],"predecessor-version":[{"id":691,"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/pages\/690\/revisions\/691"}],"wp:attachment":[{"href":"https:\/\/aslabsci.com\/en\/wp-json\/wp\/v2\/media?parent=690"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}